KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Short term Debt: 2010-2024

Historic Short term Debt for Pacira BioSciences (PCRX) over the last 12 years, with Dec 2024 value amounting to $201.8 million.

  • Pacira BioSciences' Short term Debt was N/A to $202.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was $202.4 million, marking a year-over-year change of. This contributed to the annual value of $201.8 million for FY2024, which is 2235.10% up from last year.
  • According to the latest figures from FY2024, Pacira BioSciences' Short term Debt is $201.8 million, which was up 2,235.10% from $8.6 million recorded in FY2023.
  • Pacira BioSciences' Short term Debt's 5-year high stood at $350.5 million during FY2021, with a 5-year trough of $8.6 million in FY2023.
  • For the 3-year period, Pacira BioSciences' Short term Debt averaged around $81.4 million, with its median value being $33.6 million (2022).
  • Its Short term Debt has fluctuated over the past 5 years, first crashed by 90.40% in 2022, then skyrocketed by 2,235.10% in 2024.
  • Over the past 5 years, Pacira BioSciences' Short term Debt (Yearly) stood at $149.6 million in 2020, then skyrocketed by 134.19% to $350.5 million in 2021, then crashed by 90.40% to $33.6 million in 2022, then tumbled by 74.32% to $8.6 million in 2023, then surged by 2,235.10% to $201.8 million in 2024.